Company & Product Profile
The master record that makes the software contextual, not just a pretty agenda.
BaiOS turns an assay into a living plan. Performance evaluation and the conformity route, runway and European funding, all in one place. It is not task management. It tells you which study to buy with the cash you have.
The in vitro diagnostic regulation (IVDR) moved most tests into notified body scope. The plans did not move with it. A spreadsheet does not know that a notified body queue is on your critical path. BaiOS does.
The founder runs assay development, funding and the board update alone, with no CFO, no PMO and no regulatory or quality lead.
First revenue and the next round are different dates with different requirements, and the financial model only has room for one of them.
Scientific validity, analytical performance and clinical performance are three studies with three budgets and three durations, tracked outside the financial model.
The wait for a conformity assessment slot is a real date on the critical path. It rarely appears on a plan until it is late.
A CE mark is permission to sell, not a decision to pay. The coding and coverage work starts after the launch date is already promised.
CDTI, ENISA, EIC, Eurostars, equity and loans, each with its own timing and eligible costs. All of it planned in disconnected spreadsheets.
The gate ↔ money relationship is the soul of the product. Change one assumption and the runway, the gates and the funding gap move with it.
Anyone can tell a founder they have twelve months of cash. The useful sentence names the next milestone, what it costs and what unlocks it. Change one assumption and the runway, the gates and the funding gap all move with it.
R&D planning is what has to be proven. Financial planning is what it costs and who pays for it. Nothing here is independent: a change in the intended use moves the cost, the timeline, the risk and the story with it.
The master record that makes the software contextual, not just a pretty agenda.
Intended use and performance claims kept alive, not a dead PDF. They are the base of every assumption.
A development roadmap you build against your own conformity route, every step costed and dated.
The differentiator: decision gates you define for your pathway. Criteria and go/no-go, not a task list.
Whether the team can actually run the plan, and the CROs and CDMOs it depends on.
Living risks with runway impact, and the patent families and exclusivity date the plan has to fit inside.
Beyond cash in, cash out: burn-to-milestone and cash-out date.
What each milestone costs, what is funded and what is still missing. Per milestone, not in a total.
Equity, grants, loans and business development in one place. It is the European non-dilutive map that US tools ignore.
Every assumption automatically impacts cash, milestones and reporting.
Population, uptake and pricing. It is the revenue line the whole plan is aiming at.
The investor and board figures, on one screen, reading from the live plan.
Every alternative owns one slice of the problem. BaiOS ties gate ↔ money together, with European funding logic and Adbaio advisory built in. None of the others have that.
Greenlight Guru and Qualio hold the quality record beautifully. Neither tells you which study to buy with the cash you have, or what it unlocks.
Task tools (Asana, Notion, Monday) have no diagnostics logic: no gates, no product profile, no runway that knows what a milestone is.
Runway and Pigment don't know what a performance evaluation is, or that revenue and the next round are two different clocks.
BaiOS plans the company. It does not write your technical documentation, and it does not pretend the conformity route is automatable.
The venture tools built for this market ignore IVDR and ignore European public funding entirely.
Adbaio without BaiOS is a great plan that goes stale in a PDF. BaiOS without Adbaio is eighty empty fields a founder abandons. Together they are a living plan with expert judgement embedded in it. The software retains, the advisory reviews it monthly.
Monthly, no lock-in. Prices exclude VAT; 21% is added at checkout for Spanish buyers.
€220/mo
€280/mo
€390/mo
From a working assay to the next financeable or revenue-generating milestone. Set it up before you pitch, not after.